New hope for kids with Tough-to-Treat bone cancer

NCT ID NCT06341712

Summary

This study is testing if adding a daily pill called cabozantinib to standard supportive care helps control osteosarcoma (a type of bone cancer) for longer in children and young adults whose cancer cannot be fully removed by surgery. Participants, aged 5 to 30, will be randomly assigned to receive either cabozantinib plus supportive care or supportive care alone. The main goal is to see if the drug delays the cancer from getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AOU Città della Salute e della Scienza di Torino

    Piemonte, Italy

  • Amsterdam UMC - Locatie AMC

    Amsterdam, Netherlands

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Centre Oscar Lambret

    Lille, France

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia, 23507, United States

  • Dr. von Haunerschen Kinderspital

    München, Germany

  • Hospital Infantil Universitario Nino Jesus

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain

  • Instytut Matki i Dziecka

    Warsaw, Poland

  • McGill University Health Centre - Centre for Innovative Medicine

    Québec, Canada

  • Ospedale Ortopedico Rizzoli di Bologna

    Bologna, Italy

  • Princess Margaret cancer center

    Toronto, Canada

  • University Hospital Gent

    Ghent, Belgium

  • Universitätsmedizin Mainz

    Mainz, Germany

Conditions

Explore the condition pages connected to this study.